Company Filing History:
Years Active: 2023
Title: Fiona Chester: Innovator in Cancer Immunotherapy
Introduction
Fiona Chester is a prominent inventor based in Abingdon, GB. She has made significant contributions to the field of cancer immunotherapy, particularly through her innovative work on T cell receptors.
Latest Patents
Fiona holds a patent for "T cell receptors specific for the NY-ESO-1 tumor antigen-HLA-A*02 complex." This invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide SLLMWITQC derived from the cancer antigen NY-ESO-1. The TCRs may include mutations within the alpha and/or beta variable domains compared to a native NY-ESO-1 TCR. These TCRs are particularly suitable for use as novel immunotherapeutic agents for the treatment of malignant diseases.
Career Highlights
Throughout her career, Fiona has worked with notable companies in the biotechnology sector, including Immunocore Limited and Adaptimmune Limited. Her work has been instrumental in advancing the understanding and treatment of cancer through innovative immunotherapeutic approaches.
Collaborations
Fiona has collaborated with esteemed colleagues such as Andrew Alexander Knox and Jonathan Patrick Lowther. These partnerships have further enhanced her research and development efforts in the field of cancer immunotherapy.
Conclusion
Fiona Chester's contributions to cancer immunotherapy through her patented innovations highlight her role as a leading inventor in the field. Her work continues to pave the way for new treatments that can significantly impact patient outcomes.